# Victor Shi

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/victor-shi/

## Facts

| Field | Value |
| --- | --- |
| Citations | 25,218 |
| Field | Heart Failure Treatment and Management |
| h-index | 62 |
| i10-index | 102 |
| Last Known Institution | Novartis (Switzerland) |
| OpenAlex ID | https://openalex.org/A5110501257 |
| ORCID iD | https://orcid.org/0000-0002-2533-4379 |
| Works | 158 |

## Researcher papers

- [Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure](https://scholariq.org/papers/angiotensin-neprilysin-inhibition-versus-enalapril-in-heart-failure/)
- [Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction](https://scholariq.org/papers/angiotensin-neprilysin-inhibition-in-heart-failure-with-preserved-ejection/)
- [Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients](https://scholariq.org/papers/benazepril-plus-amlodipine-or-hydrochlorothiazide-for-hypertension-in-high-risk/)
- [The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial](https://scholariq.org/papers/the-angiotensin-receptor-neprilysin-inhibitor-lcz696-in-heart-failure-with/)
- [Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure](https://scholariq.org/papers/angiotensin-receptor-neprilysin-inhibition-compared-with-enalapril-on-the-risk/)
- [Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure](https://scholariq.org/papers/sacubitril-valsartan-across-the-spectrum-of-ejection-fraction-in-heart-failure/)
- [Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure](https://scholariq.org/papers/renal-effects-and-associated-outcomes-during-angiotensin-neprilysin-inhibition/)
- [Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction](https://scholariq.org/papers/effects-of-sacubitril-valsartan-versus-valsartan-in-women-compared-with-men-with/)
- [Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction](https://scholariq.org/papers/risk-related-to-pre-diabetes-mellitus-and-diabetes-mellitus-in-heart-failure/)
- [Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction](https://scholariq.org/papers/angiotensin-neprilysin-inhibition-and-renal-outcomes-in-heart-failure-with/)
- [Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction](https://scholariq.org/papers/effect-of-sacubitril-valsartan-vs-standard-medical-therapies-on-plasma-nt-probnp/)

## Researcher topics

- [Heart Failure Treatment and Management](https://scholariq.org/topics/heart-failure-treatment-and-management/)
- [Cardiovascular Function and Risk Factors](https://scholariq.org/topics/cardiovascular-function-and-risk-factors/)
- [Blood Pressure and Hypertension Studies](https://scholariq.org/topics/blood-pressure-and-hypertension-studies/)
- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Cardiac pacing and defibrillation studies](https://scholariq.org/topics/cardiac-pacing-and-defibrillation-studies/)

## Researcher university

- [Novartis (Switzerland)](https://scholariq.org/institutions/novartis-switzerland/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.